Valuation : Definium Therapeutics, Inc.

Market Cap 5.1B 4.39B 4.14B 3.77B 7.05B 486B 7.08B 49.02B 18.95B 247B 19.17B 18.75B 784B P/E 2026 *
-12x
P/E 2027 * -19x
Enterprise Value 4.05B 3.48B 3.28B 2.99B 5.59B 385B 5.62B 38.88B 15.03B 196B 15.2B 14.87B 622B EV / Sales 2026 *
-
EV / Sales 2027 * 136x
Free-Float
98.26%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Definium Therapeutics, Inc.

1 day-0.63%
1 week-2.34%
Current month-4.36%
1 month-17.66%
3 months+65.53%
6 months+107.03%
Current year+183.72%
1 week 37.38
Extreme 37.38
39.26
1 month 37.32
Extreme 37.32
47.55
Current year 12.88
Extreme 12.882
49.7
1 year 8.77
Extreme 8.7732
49.7
3 years 2.41
Extreme 2.41
49.7
5 years 2.12
Extreme 2.12
49.7
10 years 1.25
Extreme 1.249499
86.55
Manager TitleAgeSince
Chief Executive Officer 37 2021-06-08
Director of Finance/CFO 52 2025-06-01
Chief Tech/Sci/R&D Officer 46 2021-01-31
Director TitleAgeSince
Director/Board Member 37 2021-12-12
Director/Board Member 67 2021-09-28
Chairman 69 2021-12-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Sell

Chief Executive Officer

-19,023 0.0143%
8/12/26 Free

Chief Financial Officer

62,500 0.0471%
8/12/26 Free

General Counsel

62,500 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-2.34%+288.84%+852.13% 5.1B
+0.59%-6.98%-2.73%+11.12% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
+0.51%-3.76%+12.33%+30.49% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -0.61%-2.83%+94.69%+193.43% 27.21B
Weighted average by Cap. -0.33%-3.03%+90.03%+147.43%

Financials

2026 *2027 *
Net sales - 31.42M 27.04M 25.46M 23.2M 43.4M 2.99B 43.57M 302M 117M 1.52B 118M 115M 4.83B
Net income -376M -324M -305M -278M -519M -35.79B -522M -3.61B -1.4B -18.23B -1.41B -1.38B -57.76B -273M -235M -221M -202M -377M -25.98B -379M -2.62B -1.01B -13.24B -1.03B -1B -41.94B
Net Debt -1.06B -908M -855M -779M -1.46B -100B -1.46B -10.14B -3.92B -51.18B -3.96B -3.88B -162B -845M -727M -685M -624M -1.17B -80.41B -1.17B -8.11B -3.14B -40.97B -3.17B -3.1B -130B
Logo Definium Therapeutics, Inc.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Employees
-
Date Price Change Volume
26-09-09 US$37.99 -0.63% 1,285,383
26-09-08 US$38.23 +0.37% 1,494,413
26-09-04 US$38.09 +0.24% 1,128,929
26-09-03 US$38.00 -2.31% 1,529,868
26-09-02 US$38.90 +1.04% 1,429,217
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
37.99USD
Average target price
67.47USD
Spread / Average Target
+77.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DFTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!